Cornell Pochily Investment Advisors Inc. Acquires 19,609 Shares of Kenvue Inc. $KVUE

Cornell Pochily Investment Advisors Inc. raised its holdings in shares of Kenvue Inc. (NYSE:KVUE) by 144.6% in the 2nd quarter, Holdings Channel.com reports. The firm owned 33,173 shares of the company’s stock after buying an additional 19,609 shares during the quarter. Cornell Pochily Investment Advisors Inc.’s holdings in Kenvue were worth $694,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of KVUE. Cambridge Investment Research Advisors Inc. lifted its holdings in shares of Kenvue by 4.0% in the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 106,140 shares of the company’s stock worth $2,545,000 after acquiring an additional 4,034 shares during the last quarter. Renaissance Capital LLC lifted its holdings in shares of Kenvue by 8.3% in the 2nd quarter. Renaissance Capital LLC now owns 629,177 shares of the company’s stock worth $13,169,000 after acquiring an additional 48,267 shares during the last quarter. Farther Finance Advisors LLC lifted its holdings in shares of Kenvue by 80.7% in the 2nd quarter. Farther Finance Advisors LLC now owns 36,196 shares of the company’s stock worth $758,000 after acquiring an additional 16,164 shares during the last quarter. Arlington Partners LLC bought a new stake in shares of Kenvue in the 2nd quarter worth about $2,110,000. Finally, IFP Advisors Inc lifted its holdings in shares of Kenvue by 25.3% in the 1st quarter. IFP Advisors Inc now owns 15,278 shares of the company’s stock worth $369,000 after acquiring an additional 3,081 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

Kenvue Trading Down 0.9%

Shares of KVUE opened at $15.72 on Friday. Kenvue Inc. has a 1-year low of $15.47 and a 1-year high of $25.17. The company has a 50-day moving average of $19.85 and a 200 day moving average of $21.63. The firm has a market capitalization of $30.16 billion, a price-to-earnings ratio of 21.24, a PEG ratio of 2.28 and a beta of 0.72. The company has a debt-to-equity ratio of 0.66, a current ratio of 0.98 and a quick ratio of 0.68.

Kenvue (NYSE:KVUE) last announced its quarterly earnings data on Thursday, August 7th. The company reported $0.29 earnings per share for the quarter, beating analysts’ consensus estimates of $0.28 by $0.01. Kenvue had a net margin of 9.37% and a return on equity of 20.06%. The company had revenue of $3.84 billion during the quarter, compared to analyst estimates of $3.94 billion. During the same quarter last year, the business posted $0.32 EPS. The firm’s revenue for the quarter was down 4.0% on a year-over-year basis. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. On average, research analysts expect that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, August 27th. Shareholders of record on Wednesday, August 13th were given a dividend of $0.2075 per share. This is a positive change from Kenvue’s previous quarterly dividend of $0.21. The ex-dividend date of this dividend was Wednesday, August 13th. This represents a $0.83 dividend on an annualized basis and a yield of 5.3%. Kenvue’s payout ratio is 112.16%.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on KVUE. Citigroup restated a “neutral” rating on shares of Kenvue in a report on Tuesday, September 23rd. Evercore ISI lowered their target price on shares of Kenvue from $23.00 to $18.00 and set an “in-line” rating for the company in a report on Tuesday, September 23rd. UBS Group lowered their target price on shares of Kenvue from $25.00 to $23.00 and set a “neutral” rating for the company in a report on Thursday, July 17th. Bank of America decreased their price objective on shares of Kenvue from $27.00 to $25.00 and set a “buy” rating for the company in a report on Tuesday, July 15th. Finally, JPMorgan Chase & Co. decreased their price objective on shares of Kenvue from $27.00 to $26.00 and set an “overweight” rating for the company in a report on Friday, July 25th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Kenvue presently has a consensus rating of “Hold” and an average price target of $22.46.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.